+919405117673
Rucaparib Tablets 200MG/250MG/300MG Online Purchase in USA from India
Rucaparib Tablets 200MG, 250MG and 300MG are oral prescription medicines containing rucaparib, a PARP inhibitor used in specific cancer treatment settings. For international pharmaceutical buyers, hospitals, distributors and authorized healthcare channels in the USA, Cordium Pharmaceuticals Pvt Ltd provides pharmaceutical sourcing and export support from India, subject to applicable prescription and import regulations.

Rucaparib Tablets 200MG/250MG/300MG Supplier from India

Cordium Pharmaceuticals Pvt Ltd supports international buyers looking for Rucaparib tablets from India in 200MG, 250MG and 300MG strengths. Buyers can contact the company for product availability, quotation, documentation, packaging requirements and export-related information.

Rucaparib is marketed in the USA under the brand Rubraca. The current U.S. labeling identifies rucaparib as a PARP inhibitor and lists 200MG, 250MG and 300MG tablet strengths.

Rucaparib Tablets Online Purchase in USA from India

Customers searching for Rucaparib tablets online purchase in USA from India should use authorized pharmaceutical supply channels and verify all prescription, import and regulatory requirements before placing an order. Rucaparib is a prescription medicine, so supply should be handled according to applicable laws and healthcare-provider requirements.

Cordium Pharmaceuticals Pvt Ltd can assist eligible international buyers with enquiries for Rucaparib 200MG, Rucaparib 250MG and Rucaparib 300MG, including quotation and export documentation requirements.

Rucaparib 200MG, 250MG and 300MG Tablets

Rucaparib tablets are available in three strengths:

Rucaparib 200MG Tablets
Rucaparib 250MG Tablets
Rucaparib 300MG Tablets

The FDA-approved U.S. labeling states that the recommended dose for Rubraca is 600MG orally twice daily, with dose modifications possible for adverse reactions. Treatment decisions and dosing must be made by the prescribing healthcare professional.

Rucaparib Uses

Rucaparib is a PARP inhibitor. According to the current U.S. prescribing information, it is indicated for maintenance treatment of certain adults with BRCA-mutated recurrent ovarian, fallopian tube or primary peritoneal cancer following a response to platinum-based chemotherapy. It is also indicated for certain adults with BRCA-mutated metastatic castration-resistant prostate cancer previously treated with androgen receptor-directed therapy.

Rucaparib Export from India to USA

Cordium Pharmaceuticals Pvt Ltd supports pharmaceutical buyers seeking Rucaparib export from India to USA. International orders can be discussed based on product strength, quantity, packaging, shipping requirements and applicable regulatory documentation.

For U.S. buyers, importation of prescription medicines is subject to U.S. laws and regulatory requirements. Buyers should confirm eligibility and compliance before purchasing or importing pharmaceutical products.

Rucaparib Packaging and Storage

U.S. labeling lists Rucaparib tablets in bottles containing 60 tablets for the 200MG, 250MG and 300MG strengths. The labeled storage condition is 20°C to 25°C (68°F to 77°F), with permitted excursions from 15°C to 30°C (59°F to 86°F).

Proper pharmaceutical packaging and storage should be maintained throughout transportation and delivery.

Why Choose Cordium Pharmaceuticals Pvt Ltd?

Cordium Pharmaceuticals Pvt Ltd provides pharmaceutical sourcing and export assistance from India for international buyers. Customers can enquire about:

Rucaparib 200MG, 250MG and 300MG tablets
Bulk pharmaceutical requirements
Product availability and quotations
Export packaging requirements
Commercial and shipping documentation
International pharmaceutical supply support
Request a Rucaparib Quote from India

If you are a pharmaceutical distributor, hospital procurement team, authorized importer or eligible healthcare buyer in the USA looking for Rucaparib tablets from India, contact Cordium Pharmaceuticals Pvt Ltd for product availability and a quotation.
Sep 11th, 2026 4:42 PM

Keywords